scholarly journals Hirsutism, Acne, and Hair Loss: Management of Hyperandrogenic Cutaneous Manifestations of Polycystic Ovary Syndrome

2016 ◽  
pp. 1
Author(s):  
Cenk Yasa ◽  
Özlem Dural ◽  
Ercan Bastu ◽  
Funda Güngör Uğurlucan
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Androgenic Alopecia ◽  
Ovary Syndrome ◽  
Cutaneous Manifestations ◽  
Insulin Sensitizers ◽  
Criteria For Diagnosis ◽  
Reproductive Aged Women ◽  
Topical Medications ◽  
Endocrine Abnormality

<p>PPolycystic ovary syndrome is the most common endocrine abnormality that affects reproductive-aged women. Diagnostic criteria of polycystic ovary syndrome have been established by different societies in recent years, and hyperandrogenism remains as one of the main criteria for diagnosis. Cutaneous manifestations of hyperandrogenism include hirsutism, acne and androgenic alopecia and are commonly observed in women with polycystic ovary syndrome. The major determinants of cutaneous manifestations are increased production of androgen and increased tissue availability. Cutaneous manifestations of hyperandrogenism are cosmetic problems, which produce significant emotional distress and psychological morbidity. Treatment includes a combination of combined oral contraceptives, antiandrogens, insulin sensitizers, gonadotropin releasing hormone agonists, topical medications, and cosmetic procedures. The diagnosis, management, and treatment approaches are described in detail in this review.</p>

Insulin Sensitizers for Polycystic Ovary Syndrome

2003 ◽  
Vol 46 (2) ◽  
pp. 325-340 ◽  
Author(s):  
JEAN-PATRICE BAILLARGEON ◽  
MARIA J. IUORNO ◽  
JOHN E. NESTLER
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Insulin Sensitizers

High level of C-type natriuretic peptide induced by hyperandrogen-mediated anovulation in polycystic ovary syndrome mice

2018 ◽  
Vol 132 (7) ◽  
pp. 759-776 ◽  
Author(s):  
Xiao Wang ◽  
Huarong Wang ◽  
Wei Liu ◽  
Zhiyuan Zhang ◽  
Yanhao Zhang ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Natriuretic Peptide ◽  
Polycystic Ovary ◽  
Germinal Vesicle ◽  
Ovary Syndrome ◽  
Oocyte Meiosis ◽  
Type C ◽  
High Level ◽  
Reproductive Aged Women ◽  
Insight Into

Polycystic ovary syndrome (PCOS), which is characterized by hyperandrogenism, is a complex endocrinopathy that affects the fertility of 9–18% of reproductive-aged women. However, the exact mechanism of PCOS, especially hyperandrogen-induced anovulation, is largely unknown to date. Physiologically, the natriuretic peptide type C/natriuretic peptide receptor 2 (CNP/NPR2) system is essential for sustaining oocyte meiotic arrest until the preovulatory luteinizing hormone (LH) surge. We therefore hypothesized that the CNP/NPR2 system is also involved in PCOS and contributes to arresting oocyte meiosis and ovulation. Here, based on a dehydroepiandrosterone (DHEA)-induced PCOS-like mouse model, persistent high levels of CNP/NPR2 were detected in anovulation ovaries. Meanwhile, oocytes arrested at the germinal vesicle stage correlated with persistent high levels of androgen and estrogen. We further showed that ovulation failure in these mice could be a result of elevated Nppc/Npr2 gene transcription that was directly increased by androgen (AR) and estrogen (ER) receptor signaling. Consistent with this, anovulation was alleviated by administration of either exogenous human chorionic gonadotropin (hCG) or inhibitors of AR or ER to reduce the level of CNP/NPR2. Additionally, the CNP/NPR2 expression pattern in the anovulated follicles was, to some extent, consistent with the clinical expression in PCOS patients. Therefore, our study highlights the important role an overactive CNP/NPR2 system caused by hyperandrogenism in preventing oocytes from maturation and ovulation in PCOS mice. Our findings provide insight into potential mechanisms responsible for infertility in women with PCOS.

scholarly journals Insulin-sensitizing agents in polycystic ovary syndrome

2006 ◽  
Vol 154 (6) ◽  
pp. 763-775 ◽  
Author(s):  
Renato Pasquali ◽  
Alessandra Gambineri
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Plasminogen Activator Inhibitor ◽  
Normal Weight ◽  
Ovary Syndrome ◽  
Insulin Sensitizer ◽  
Insulin Resistant ◽  
Insulin Sensitizers ◽  
Activator Inhibitor Type ◽  
Almost All

Insulin-sensitizing agents have been recently proposed as the therapy of choice for polycystic ovary syndrome (PCOS), since insulin resistance and associated hyperinsulinemia are recognized as important pathogenetic factors of the syndrome. Moreover, since almost all obese PCOS women and more than half of those of normal weight are insulin resistant, and therefore present some degree of hyperinsulinemia, the use of insulin sensitizers should be suggested in most patients with PCOS. Insulin sensitizer treatment has been associated with a reduction in serum androgen levels and gonadotropins, and with an improvement in serum lipids and in prothrombotic factor plasminogen-activator inhibitor type 1, whatever the insulin sensitizer used. This therapy has also been associated with a decrease in hirsutism and acne, and with a regulation of menses and an improvement of ovulation and fertility. Notable improvements in all these parameters have also been described after a change in lifestyle approach, particularly in the presence of obesity. Lifestyle interventions should therefore be combined with insulin sensitizers in PCOS when obesity is present.

Anti-Müllerian hormone as an indicator of reproductive health in women with obesity and concomitant polycystic ovary syndrome

2016 ◽  
Vol 88 (12) ◽  
pp. 41-44
Author(s):  
A K Durmanova ◽  
N K Otarbaev
Keyword(s):  
Body Mass Index ◽  
Lipid Metabolism ◽  
Reproductive Health ◽  
Polycystic Ovary Syndrome ◽  
Abdominal Obesity ◽  
Polycystic Ovary ◽  
Morphometric Parameters ◽  
Ovary Syndrome ◽  
Carbohydrate And Lipid Metabolism ◽  
Reproductive Aged Women

Aim. To investigate the ovarian reserve and a relationship between the level of anti-Müllerian hormone (AMH) with that of hormones in reproductive-aged women with abdominal obesity concurrent with and without polycystic ovary syndrome (PCOS). Subjects and methods. A total of 157 women aged 18 to 45 years with a body mass index (BMI) of more than 30 kg/m2 were examined. The 157 women with abdominal obesity were conventionally divided into 2 groups: 1) 20 with PCOS and 2) 137 without this condition. Morphometric parameters, the indicators of carbohydrate and lipid metabolism, and the levels of hormones, including AMH, were studied. Results. The patients with PCOS had statistically significantly elevated AMH levels (11.26±2.63 ng/ml; p

Cutaneous manifestations of the subtypes of polycystic ovary syndrome in Korean patients

2014 ◽  
Vol 29 (1) ◽  
pp. 42-47 ◽  
Author(s):  
J.S. Hong ◽  
H.H. Kwon ◽  
S.Y. Park ◽  
J.Y. Jung ◽  
J.Y. Yoon ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Cutaneous Manifestations ◽  
Korean Patients

Prevalence of androgenic alopecia in patients with polycystic ovary syndrome and characterization of associated clinical and biochemical features

2014 ◽  
Vol 101 (4) ◽  
pp. 1129-1134 ◽  
Author(s):  
Molly Quinn ◽  
Kanade Shinkai ◽  
Lauri Pasch ◽  
Lili Kuzmich ◽  
Marcelle Cedars ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Androgenic Alopecia ◽  
Ovary Syndrome ◽  
Biochemical Features
Sign in / Sign up

Export Citation Format

Share Document